louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04246931: Adherence Evaluation in COPD
Official title: Evaluation of Perception and Knowledge of Adherence to COPD Inhalation Therapy at Patient, GP and Pulmonologist Level
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adherence, Treatment
COPD
Lead sponsor: Chiesi SA/NV
Sponsor class: OTHER
First posted: 2020-01-29
Enrollment: 260
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Pulmonologists, general practicioners and COPD patients

Brief summary: The rationale of this study is to have a better understanding of the perception of the pulmonologists, general practitioners and patients of adherence (causes, main consequences, supportive tools,..) and the use of TAI-questionnaire (appreciation, usability,...) by interviewing pulmonologists \& general practitioners and a survey with patients. Based on the outcome, projects and tools can be developed to help health care professionals to motivate patients to improve adherence and to help patients to increase their adherence to inhalation therapy.


Eligibility criteria: Inclusion Criteria:

Pulmonologists or general practitioners or COPD patient (suffering from COPD treated with inhalation therapy)

Exclusion Criteria:

Not applicable

Primary outcomes:
measure: Knowledge and perception of adherence
timeFrame: Baseline
Secondary outcomes:
measure: Test of the adherence to inhalers-questionnaire (TAI)
timeFrame: Baseline
Other outcomes:
Locations:
city: Lasne
country: Belgium
facility: Medistrat
Study officials:
affiliation: Chiesi Belgium
name: Sofie Geelissen, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06109831: Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic
Official title: An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Hyperlipidemic
Lead sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Sponsor class: INDUSTRY
First posted: 2023-10-31
Enrollment: 335
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study
Primary purpose: TREATMENT

Brief summary: This is a Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Stud to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with Hyperlipidemic.


Eligibility criteria: Inclusion Criteria:

1. Regularly taking any moderate-intensity or higher dose\* of statin stabilization therapy for ≥4 weeks at screening:

   1. ASCVD risk is ultra-high risk Fasting LDL-C ≥ 1.4 mmol/L;
   2. ASCVD risk very high risk Fasting LDL-C ≥1.8 mmol/L;
   3. ASCVD risk is intermediate or high risk Fasting LDL-C ≥ 2.6 mmol/L.
2. Any other condition that is not met at screening Regularly taking any moderate intensity and higher dose\* statin stabilization therapy for ≥4 weeks;

   a) Fasting LDL-C ≥ 2.6 mmol/L.
3. Fasting triglycerides ≤ 5.6 mmol/L.

Exclusion Criteria:

1. Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes at screening (HbA1c \> 8.5%).
2. eGFR \<30ml/min/1.73m2 at the screening visit.
3. CK \>5times ULN at the screening visit.

Primary outcomes:
measure: Percent change in calculated LDL-C from baseline to week 16
timeFrame: from baseline to week 16
Secondary outcomes:
measure: Change in calculated LDL-C from baseline to week 16
timeFrame: from baseline to week 16
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT01601782: Impact of Volume Imaging Using Diagnostic Ultrasound
Official title: Impact of Volume Imaging With Ultrasound
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Bone Injuries
Muscle Injuries
Tendon Injuries
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2012-05-18
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Determine if volume imaging can diagnose bone, ligament, muscle injuries.

Detailed description: The investigators are attempting to determine if Volume imaging (a new type of ultrasound imaging)can accurately diagnose injuries of the muscle ligaments, tendons and bones when compared to conventional ultrasound imaging.

Eligibility criteria: Inclusion Criteria:

* Age 18 or older
* Must be scheduled to have a musculoskeletal (bone, ligament, muscle, tendon) ultrasound performed as part of their routine clinical care.

Exclusion Criteria:

* Unable to lie flat on ultrasound table.
* Subjects under 18 years of age

Primary outcomes:
measure: Accuracy of 3D Ultrasound Scanning Expressed as Percent Correlation Between Images From Conventional Ultrasound and Volume Imaging
timeFrame: Up to 13 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan Hospital
name: Jon Jacobson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04013282: Adrenergic Cholinergic Enteric Measures/Mapping
Official title: Adrenergic Cholinergic Enteric Measures/Mapping
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obesity
Lead sponsor: University of Louisville
Sponsor class: OTHER
First posted: 2019-07-09
Enrollment: 500
Sex: ALL
Minimum age (years): 10
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients seen

Brief summary: Patients seen who had autonomic and enteric profiling (Adrenergic, Cholinergic, Enteric Measures/Mapping=ACEM_ from 2012-2019 at the University of Louisville.

Detailed description: 1. Patients seen who had autonomic and enteric profiling (Adrenergic Cholinergic Enteric Measures/Mapping=ACEM) from 2012-2019 at the U of Louisville.
2. Results of the physiologic measures of ACEM had the results recorded.
3. ACEM is compared to standardized gastric emptying values as the primary measure.
4. ACEM is also compared to metabolic measures of weight, height and thus BMI as a secondary measure.
5. ACEM is aloes compared with standardized gastrointestinal symptoms by a traditional patient recorded outcome as another secondary measure.

Other sites may be added if they have identical IRB and/or data sharing agreements with the University of Louisville.

Eligibility criteria: Inclusion Criteria:

* Patients with the symptoms suggestive of autonomic and/or enteric disorders.

Exclusion Criteria:

* Anatomic obstruction of the GI tract
* Pregnancy
* Inability of patient or guardian to sign informed consent, if needed
* Psychiatric disorders precluding assessment and treatment of the patient's GI condition.

Primary outcomes:
measure: Body Mass Index
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Louisville
country: United States
facility: University of Louisville
state: Kentucky
Study officials:
affiliation: University of Louisville
name: Thomas Abell
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06299982: An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
Official title: A Multicenter,Randomized,Phase 3 Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Plaque Psoriasis Patients
Lead sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-03-08
Enrollment: 750
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years old, both male and female.
* Diagnosis of plaque psoriasis according to the Chinese Guideline for the Diagnosis and Treatment of Psoriasis (2018).

Exclusion Criteria:

* Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) .
* Other inflammatory diseases.
* Active autoimmune diseases.
* Pregnant or lactating women.

Primary outcomes:
measure: Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
timeFrame: At Week 12
measure: Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement
timeFrame: At Week 12
Secondary outcomes:
measure: Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
timeFrame: At Week 12
measure: Percentage of Participants Achieving a ≥100% Improvement in Psoriasis Area and Severity Index (PASI 100)
timeFrame: At Week 12
measure: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0)
timeFrame: At Week 12
measure: Adverse events (AE)
timeFrame: 20 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04560582: Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Official title: Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Kidney Transplant; Complications
Kidney Transplant Rejection
Kidney Transplant Failure
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2020-09-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study proposes to recruit adult patients primarily from the inpatient units at UMMC Fairview, or the Renal or Transplant facilities at the Clinics and Surgery Center as attended by the PI and Co-Is. Additional clinics will be recruited from depending on patient population and clinician support.

Brief summary: The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.

Detailed description: This is an observational cohort study collecting data and blood specimens at designated time points. The primary outcome will be comparing the cPRA in patients that have a rise in cf-DNA to those that do not have a rise in cf-DNA. Seondary outcomes include comparison of the combined incidence of need for transfusion, need for methylprednisolone and allograft nephrectomy, ESA dose, allograft tenderness, and gross hematuria.

Eligibility criteria: Inclusion Criteria:

* Failed allograft requiring dialysis
* No living donor available for re-transplant option or anticipated deceased donor within the next 12 months
* Patient to be enrolled prior to 3rd HD (hemodialysis) session or within 1 week of starting peritoneal dialysis

Exclusion Criteria:

* 17 years or younger
* cPRA at entrance of 100%
* Primary non-function of the allograft
* Multi-organ transplant

Primary outcomes:
measure: cPRA Concentrations
timeFrame: 1 day
measure: cf-DNA Concentrations
timeFrame: up to 24 weeks
Secondary outcomes:
measure: Incidence of Need for Transfusion
timeFrame: 24 weeks
measure: Incidence of Need for Methylprednisolone and Allograft Nephrectomy
timeFrame: 24 weeks
measure: Incidence of ESA Dose
timeFrame: 24 weeks
measure: Incidence of Allograft Tenderness
timeFrame: 24 weeks
measure: Incidence of Gross Hematuria
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minenesota
name: Adam Bregman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00420082: A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Official title: A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Seasonal Allergic Rhinitis
Keywords: Rhinitis
Seasonal
Allergic
Pollen allergy
Environmental Exposure Chamber
Challenge Chamber
Lead sponsor: Faes Farma, S.A.
Sponsor class: INDUSTRY
First posted: 2007-01-09
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20 mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.

Detailed description: The objective of the study is to determine the effect of a single dose of bilastine 20 mg on nasal symptoms of allergic rhinitis provoked by spending 4 hours in the Vienna Challenge Chamber . This effect will be compared to that action of Cetirizine 10 mg, Fexofenadine 120 mg, and placebo. To explore the onset of action, patients will receive study drug two hours after the start of the provocation on Day 1.Patients will remain in theVCC for an additional four hours. On Day 2, patients will return to the VCC post-dose hours 22-26.

Eligibility criteria: Inclusion Criteria:

* Have a history of seasonal allergic rhinitis
* Have a positive (as defined in the protocol) skin prick or RAST test within 12 months prior to the screening visit

Exclusion Criteria:

* Have a clinically significant illness or disease
* Have unstable asthma
* Has participated in a clinical trial 30 days prior to the screening visit

Primary outcomes:
measure: Onset of action and action duration
Secondary outcomes:
measure: Nasal and ocular symptom scores
measure: Nasal airflow resistance
measure: Nasal secretion weight
measure: FEV1
measure: Routine safety parameters (vital signs, ECGs, clinical laboratory tests)
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Allergy Center Vienna West
Study officials:
affiliation: ENT University Clinic Vienna
name: Friedrich Horak, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010 May;59(5):391-8. doi: 10.1007/s00011-009-0117-4. Epub 2009 Nov 27.
Clinical trial NCT00628082: Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction
Official title: Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure, Diastolic
Keywords: Cardiac Energetics
Dynamic Diastolic filling Assessment
Heart Failure with Preserved Ejection Fraction
Arterial and Ventricular Stiffening
Lead sponsor: University Hospital Birmingham
Sponsor class: OTHER
Collaborators: name: Heart of England NHS Trust
name: British Heart Foundation
First posted: 2008-03-04
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Heart Failure Clinic

Brief summary: Up to half of all patients with heart failure are found to have normal pumping function of the heart muscle, but show abnormalities in the way the heart muscle relaxes and fills with blood. These patients often have high blood pressure, and tend to have stiff arteries and stiff heart muscle. We wish to test the hypothesis that these patients have abnormal energy stores in their heart muscle.


Eligibility criteria: Inclusion Criteria:

* Clinical features consistent with heart failure
* LVEF ≥ 50%, with no evidence of significant valvular disease, no hypertrophic cardiomyopathy, and no evidence of pericardial constriction
* A peak VO2 \< 80% predicted, with a pattern of gas exchange on metabolic exercise testing indicating a cardiac cause for limitation

Exclusion Criteria:

* Objective evidence of lung disease on formal lung function testing
* Reversible myocardial ischaemia on contrast-enhanced myocardial stress
* Echocardiography, and evidence of exercise-induced mitral regurgitation
* Obesity (BMI \>35) or a locomotor cause for exercise limitation

Primary outcomes:
measure: Complete echocardiographic assessment to assess resting diastolic function
timeFrame: 1 DAY
measure: Assessment of resting large artery function
timeFrame: 1 DAY
measure: Multiple Gated Acquisition Scan
timeFrame: 1 DAY
measure: Cardiac Magnetic Resonance Spectroscopy
timeFrame: 1 DAY
measure: Metabolic Exercise Testing (VO2max)
timeFrame: 1 DAY
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: University of Birmingham
Study officials:
affiliation: University of Birmingham
name: Michael Frenneaux, FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01003782: Routine Bile Collection for Microbiological Analysis During Cholangiography
Official title: Routine Bile Collection for Microbiological Analysis During Cholangiography and Its Impact on Management of Cholangitis: Results of a Prospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cholangitis
Keywords: cholangitis
antibiotic
bacteriobilia
bile
ERCP
Lead sponsor: Hannover Medical School
Sponsor class: OTHER
First posted: 2009-10-29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients presenting to Endoscopic retrograde cholangiography

Brief summary: Background: Antibiotic treatment of cholangitis often remains insufficient due to inappropriate antibiotic use or bacterial resistance.

Objective: To evaluate the role of routine bile collection during endoscopic retrograde cholangiography (ERC) or percutaneous transhepatic cholangiography (PTC) for microbiological analysis in the antibiotic management of cholangitis and to identify risk factors of microbial growth.

Design: Prospective, observational, diagnostic study.

Setting: Hannover Medical School, Hannover, Germany. Patients and Interventions: Consecutive patients undergoing ERC/PTC for biliary complications after orthotopic liver transplantation , malignancy, primary sclerosing cholangitis, benign strictures and choledocholithiasis.

Main outcome measurements: Microbiological examination of bile samples


Eligibility criteria: Inclusion Criteria:

* age above 18 years
* written informed consent

Exclusion Criteria:

* age under 18 years
* no written informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Hannover Medical school
Study officials:
References:
Clinical trial NCT03380182: Acupuncture and Acupressure for Postoperative Nausea and Vomiting in Children Undergoing Outpatient Middle Ear Surgery
Official title: Acupuncture and Acupressure for Postoperative Nausea and Vomiting in Children Undergoing Outpatient Middle Ear Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nausea
Vomiting
PONV
Keywords: acupuncture
acupressure
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2017-12-21
Enrollment: 11
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The specific aim of this study is to determine the incidence of post-operative nausea and vomiting (PONV) in the pediatric population undergoing outpatient middle ear surgery.

Detailed description: The specific aim of this study is to determine the incidence of post-operative nausea and vomiting (PONV) in the pediatric population undergoing outpatient middle ear surgery receiving our institution's standard dual prophylactic antiemetic therapy in combination with intraoperative acupuncture and postoperative acupressure compared to those receiving only the standard dual prophylactic antiemetic therapy.

Eligibility criteria: Inclusion Criteria:

* Healthy ASA 1 and 2 Patients
* Age 2 to 18 years old
* Undergoing Outpatient Middle ear surgery

Exclusion Criteria:

* ASA 3 and above
* Patients with underlying pro-emetogenic disease
* Patients currently taking antiemetic agents
* pregnant women
* Cognitively impaired adults
* prisoners
* History of bleeding disorder
* Age less than 2 or greater than 18

Primary outcomes:
measure: The evaluation of post operative nausea and vomiting at different time points during and after hospital stay.
timeFrame: 24 hours
Secondary outcomes:
measure: number of antiemetics administered during the study period,
timeFrame: 24 hrs
measure: time to oral intake tolerance
timeFrame: 24 hrs
measure: duration of recovery room stay
timeFrame: 24 hours
measure: nausea requiring admission to hospital, emergency room or another medical care providers
timeFrame: 24 hrs
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Medical Center
state: California
Study officials:
References:
Clinical trial NCT02726282: Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey
Official title: Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Thyroid Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2016-04-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with diagnosis of thyroid nodules

Brief summary: To explore how a clinical sample of patients with thyroid nodules (men and women) with no history of thyroid cancer would make decisions about treatments based on different terminology used to describe papillary thyroid cancer (with and without the cancer term).


Eligibility criteria: Inclusion Criteria:

* able to complete a survey

Exclusion Criteria:

* None

Primary outcomes:
measure: Treatment choice
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Juan P Brito
role: PRINCIPAL_INVESTIGATOR
References: